Hazzard W R
Department of Internal Medicine, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina.
Clin Geriatr Med. 1992 Feb;8(1):89-102.
No clear consensus has emerged as to whether or not aggressive screening, surveillance, and management of lipid disorders in the elderly is indicated. Informal polling would suggest a highly conservative approach beyond age 70 but near universal support for such therapy below age 60, with gradations of enthusiasm in between. Studies to identify the cardiovascular risk factors in older persons have been initiated, as has been an intervention trial to lower elevated LDL cholesterol levels in older subjects with an HMG CoA reductase inhibitor. By the year 2000, the present, highly individualized and subjective treatment of lipid disorders in elderly patients may be replaced by more objective, uniform guidelines for such management. In the meantime the question remains, "Should dyslipoproteinemia be treated in the elderly?" And the answer remains, "Perhaps."
对于是否应对老年人的脂质紊乱进行积极筛查、监测和治疗，目前尚无明确的共识。非正式民意调查显示，70岁以上采取高度保守的方法，但60岁以下对此类治疗几乎普遍支持，介于两者之间的支持程度有所不同。已开展研究以确定老年人的心血管危险因素，也已开展一项干预试验，用HMG CoA还原酶抑制剂降低老年受试者升高的低密度脂蛋白胆固醇水平。到2000年，目前对老年患者脂质紊乱高度个体化和主观的治疗可能会被更客观、统一的管理指南所取代。与此同时，问题仍然存在：“老年血脂异常是否应接受治疗？”答案仍然是：“也许。”
